Medical News
DIPLOMA Trial: Minimally Invasive Surgery is an Effective Treatment Option for Early-Stage Pancreatic Cancer
A notable study, DIPLOMA, led by Abu Hilal, M.D., Ph.D., of the Istituto Ospedaliero Fondazione Poliambulanza in Brescia, Italy, involved a large c...
Personalized mRNA Pancreatic Cancer Vaccine Shows Promising Results in Small Trial
Messenger RNA (mRNA) vaccines – famous for preventing symptomatic infection of COVID-19—are starting to show some promise against pancreati...
ESMO Study Confirms Precision Oncology Remains Largely Inaccessible to European Cancer Patients
As a European umbrella organisation, DiCE is vocal in addressing the disparities associated with cancer patients’ access to precision medicin...
Primary and Updated Analyses for DESTINY-Gastric02 Study: Trastuzumab Deruxtecan Continues to Demonstrate Benefit in Metastatic Gastric and Gastro-oesophageal Cancer
Human Epidermal Growth receptor 2 (HER2) is a protein involved in normal cell growth, found in small amounts in almost all human cells, including s...
EU Commission Approval of Tibsovo® (Ivosidenib) in IDH1-mutated Cholangiocarcinoma
The European Commission approved the use of Tibsovo® (Ivosidenib) as monotherapy for the treatment of locally advanced or metastatic cholangiocarc...
Collaboration with COR2ED – HCC CONNECT
DiCE is pleased to collaborate with HCC CONNECT. HCC CONNECT is an international group of experts in hepatocellular carcinoma (HCC).
...
Join our Young CRC Patient Focus Group
Join DiCE’s focus group & contribute to our mission of raising awareness about the increasing incidence of colorectal cancer in young Eu...
Liver Cancer Index – The Mapping Survey Is Available Online
The survey was created to map the liver cancer treatment landscape across the EU and is now available online and disseminated among several relevan...
Primary Findings From The GLOW Study Signals Positive Momentum In The Development Of Novel Therapeutic Options For Patients With HER2-Negative Locally Advanced Unresectable Or Metastatic Gastric & GEJ Cancers
At the end of 2022, leaders of the Phase 3 clinical trial GLOW shared their positive primary findings. GLOW (NCT03653507) is a global, multicenter,...
Trastuzumab Deruxtecan Meets Objective Response Rate Endpoint in Several Types of HER2-expressing Advanced Solid Tumours
Positive topline results of the ongoing DESTINY-PanTumour02 Phase II trial (NCT04482309) showed that treatment with trastuzumab deruxtecan met the...
- « Previous Page
- 1
- 2
- 3
- 4
- ...
- 8
- Next Page »
